Daiichi Sankyo Closes Indian Research Division
January 18, 2017
Daiichi Sankyo has closed its Mumbai, India research division as part of the company’s strategy to narrow its focus to cancer research, India's Economic Times reports. The Daiichi Sankyo India Pharma Limited (DSIN) was established in 2007 and employs about 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline will be transferred to Daiichi Sankyo’s R&D Division. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/daiichi-shuts-india-rd-division/articleshow/56486750.cms
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
